NEWS COMMENTARY

Pear Therapeutics acquires DTx assets used to treat depression, in sign of a warming market for tech-aided therapy

Published:
December 22, 2021
Last Updated:
December 27, 2021
Services:
CPG More...
Priorities:
Consumer Health and Wellness More...
Activities:
Acquisition
Very important

The acquisition of Waypoint Health Innovations further underscores Pear’s focus on its psychiatry portfolio. Before this acquisition, Pear already had a product in its development pipeline (Pear-015). Waypoint's assets deliver cognitive behavioral therapy that dynamically personalizes each individual’s experience. The treatment of depression is a large market, with 4.7% of American adults, around 12 million people, experiencing regular symptoms of depression. This market is expected to grow further with the challenges brought on by the pandemic era. Clients should move quickly to identify suitable investment or partnership opportunities at the intersection of digital therapeutics (DTx) and mental health.

For the original news article, click here .


Further Reading

Noom raises $540 million in Series F funding, aims to expand digital wellness platform

News Commentary | June 08, 2021

The round was led by Silver Lake Partners, and the company plans to use the funds to expand its health platform into virtual treatments for diabetes, hypertension, stress, and sleep. Noom has previously found success in using its behavioral coaching therapy in weight management, and its approach can... To read more, click here.

Monogram raises $160 million in Series B funding for kidney disease management

News Commentary | June 11, 2021

Monogram Health develops a digital benefits management platform, which partners with health plans to provide care for patients with chronic kidney disease (CKD). The company claims to cut healthcare costs through AI‑enabled initiatives, which can identify at‑risk patients, and personalize their care... Not part of subscription

News Trends: Digital health Q1 2022 update

Research Brief | April 21, 2022

The first quarter of 2022 saw a number of interesting developments across the many different verticals of digital health. Partnerships, acquisitions, funding, and product developments over a variety of markets have grown since the end of 2021. Partnerships across the world of digital therapeutics... Not part of subscription